Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5893897 | 1.00 | JAK3 (0.46) | JAK3MAP3K11NTRK1CHEK1PRKD3 | |
| SCHEMBL5873947 | 0.84 | MAP3K11 (0.42) | JAK3MAP3K11CHEK1PDGFRBPDGFRA | |
| SCHEMBL5893958 | 0.84 | MAP3K11 (0.42) | JAK3MAP3K11CHEK1PDGFRBPDGFRA | |
| SCHEMBL5873799 | 0.83 | MAP3K11 (0.39) | JAK3MAP3K11NTRK1RETRPS6KA3 | |
| SCHEMBL6806263 | 0.83 | MAP3K11 (0.39) | JAK3MAP3K11NTRK1RETRPS6KA3 | |
| SCHEMBL5873655 | 0.80 | NTRK1 (0.49) | JAK3MAP3K11NTRK1FLT3ALDH1A1 | |
| SCHEMBL7543661 | 0.80 | NTRK1 (0.49) | JAK3MAP3K11NTRK1FLT3ALDH1A1 | |
| SCHEMBL5893904 | 0.80 | NTRK1 (0.49) | JAK3MAP3K11NTRK1FLT3ALDH1A1 | |
| SCHEMBL6872582 | 0.75 | CDK9 (0.40) | JAK3MAP3K11NTRK1CHEK1PRKD3 | |
| SCHEMBL6872584 | 0.75 | CDK9 (0.40) | JAK3MAP3K11NTRK1CHEK1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | HARRIS PHILIP ANTHONY (US) | 2004-04-15 | — | — | US | disclosed |
| US-6624171-B1 | Useful as cyclin dependent kinase 11 inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar- palmar syndrome, mucositis) induced by chemotherapy and/or radiation therapy | SMITHKLINE BEECHAM CORPORATION | 2003-09-23 | — | — | US | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | JAK3 439/4885MAP3K11 75/4885NTRK1 1323/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | JAK3 173/4885MAP3K11 97/4885NTRK1 1095/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | JAK3 29/4885MAP3K11 270/4885NTRK1 983/4885 |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | CCNI, AZI2, CDKN1A | JAK3 294/4885MAP3K11 459/4885NTRK1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.